Skip to main content

Competition Title: Cancer Innovation Challenge – Innovative data science solutions to improve cancer care and outcomes in Scotland - PHASE 2
 

INVITATION TO TENDER (ITT)

This Invitation to Tender should be read in conjunction with other information associated with this competition and is only made available to companies successful in Phase 1. 
 

SUMMARY

Applicants are invited to tender for projects under SBRI to develop Innovative data science solutions to improve cancer care and outcomes in Scotland as outlined in the Competition Brief.

SBRI is operating under Pre-Commercial Procurement (PCP) principles. PCP is the procurement of research and development of new innovative solutions before they are commercially available. PCP involves different suppliers competing through different phases of development, where the risks and benefits related to the intellectual property rights (IPRs) resulting from the research and development (R&D) with suppliers are shared between the procurers and the suppliers under market conditions.

 

APPLICATION PROCESS

All bids should be made using the Application Form on the online submissions platform Submittable.

All applications will be treated in confidence.

Details of the background, challenges and expected outcomes of the projects can be found in the Call Brief. Guidance for completing the application form is available on the form itself. 

SBRI provides innovative solutions to challenges faced by the public sector, leading to better public services and improved efficiency and effectiveness. It supports economic growth and enables the development of innovative products and services through the public procurement of R&D.  It generates new business opportunities for companies, provides businesses with a route to market for their ideas and bridges the seed funding gap experienced by many early stage companies.

The competition has two phases. Phase 1 is intended to show the technical feasibility of the proposed concept. The development contracts awarded for Phase 1 was for a maximum duration of 3 months. A total of up to £175,000 (inclusive of VAT) funding was made available and 3 projects of up to £35,000 (inc VAT) each were supported. At this stage contracts will be let for Phase 1 only,   

Phase 2 contracts are intended to develop and evaluate proof of concepts from the more promising technologies in Phase 1, and the total funding will be up to £280,000* (inclusive of VAT).  Phase 2 contracts may be awarded to selected Phase 1 Contractors. Up to two Phase 1 Contractors are expected to be awarded Phase 2 contracts of up to £140,000* (inclusive of VAT) each.  Phase 2 is only open to organisations that have completed Phase 1 and are expected to complete an application process for Phase 2 towards the end of Phase 1. Phase 2 will follow a similar selection process.  Phase 2 contracts are expected to be for a duration of up to 6 months.

The Application Form can only be accessed via the Cancer Innovation Challenge’s Submittable site and the other ITT documents will be accessible to the Phase 1 contractors after 30 April 2018. The online form should be completed and submitted as directed. We strongly advise that you take note of the guidance provided for each question on the application form.

The competition closes at midnight (GMT) on 17 June 2018. All entries must be submitted in accordance with the directions on the Submittable platform 

PLEASE DO NOT SEND COMPLETED APPLICATIONS BY POST OR BY ANY OTHER MEANS THAN AS DIRECTED.

If you have any queries about the application process, please contact info [at] cancerchallengescotland.com (subject: PROMs%20PREMs%20Phase%202%20ITT%20query)

*the amount available for Phase 2 has increased from the original competition brief to £280,000 (inc VAT) – up to two projects to be awarded up to £140,000 (inc VAT) each
 

APPLY NOW


JOINT BIDS

Two or more Phase 1 contractors may submit a combined bid for a Phase 2 contract. Conditions for this approach are:

  • There must be a clear lead applicant/contractor
  • An agreement on potential IP entanglements must be reached by the contractors before submitting an application because once the final decision is made, the Phase 2 contract will be with the lead applicant who will take on responsibility for the contract 

 

KEY DATES

Applications deadline: Midnight (GMT), 17 June 2018
Interview with Strategic Management Board: 4 July 2018 in Edinburgh
Notification of outcome: 5 July 2018
Contracts awarded: end July 2018
Expected Phase 2 start date: 30 July 2018 (will depend on how quick contracts can be executed - allow for up to 14 days flexibility on this date)
Feedback provided by: Expected mid August 2018 

 

ASSESSMENT

Applications will be reviewed by the Cancer Innovation Challenge Strategic Management Board.  The Strategic Management Board will make the final funding decision based on three elements:

The decision will be made by the Strategic Management Board on 4 July 2018 after all Phase 1 projects have attended their interview. Contracts will be awarded shortly thereafter.  Feedback to unsuccessful applicants will be given after contracts are awarded.
 

Each element will be assessed by different criteria and a total score (sum of all three elements) will be awarded to each project. Each assessment criteria will also carry a different weighting.

 

Part A. End of Phase 1 Report Assessment Criteria

Criteria

Score

Weighting

1. Relevance to brief/scope and Feasibility
How well did the proposed solution meet the challenge as detailed in the brief? How feasible was it?

Out of 5

20%

2. Technical & Innovation
How valid was the technical approach used? How innovative was it? To what extent does the project develop or employ novel concepts, approaches, methodologies, tools or technologies for this area? How well did the project handle data access?

Out of 5

20%

3. Project management
How did the proposal demonstrate a clear management plan? How well did they manage risks?

Out of 5

10%

4. Capabilities of team
To what extent did the project involve people with the right skills, capabilities and experience to deliver the intended benefits?

Out of 5

10%

5. Stakeholder engagement
Has the applicant demonstrated meaningful stakeholder (clinical, academic, policy, administrative, ehealth) and patient/citizen engagement in Phase 1?

Out of 5

10%

6. Finance
Has the project demonstrated that the funds in Phase 1 awarded were spent appropriately and all spend justified?

Out of 5

10%

7. Commercialisation potential
Did Phase 1 demonstrate a clear commercial potential to lead to a marketable product, process or service and a clear plan to deliver that and route to market? During Phase 1, did the project demonstrate how significant the competitive advantage which this technology affords over existing/alternate technologies that can meet the market needs?

Out of 5

20%

 

Part B. Phase 2 Application Assessment Criteria

Criteria

Score

Weighting

1. Relevance to brief/scope and Intended Outputs
How well does the proposed solution meet the challenge as detailed in the brief? How feasible (based on Phase 1 work) and relevant to the brief are the intended outputs? 

Out of 5

15%

2. Technical & Innovation
How valid is the technical approach that will be adopted? How innovative is this project? To what extent does the project develop or employ novel concepts, approaches, methodologies, tools or technologies for this area?

Out of 5

15%

3. Project management
How does the proposal demonstrate that there is a clear management plan? What are the risks (technical, commercial and environmental) to project success? How effectively will these be managed? How appropriate are the milestones and evaluation procedures?

Out of 5

10%

4. Capabilities of team
To what extent does the applicant appear to have the right skills, capabilities and experience to deliver the intended benefits? Does the application demonstrate support by the mentioned external parties in the team i.e. letters of support/intent from relevant Health Board clinical and eHealth/management teams?

Out of 5

10%

5. Stakeholder engagement
Does the application include applied learnings from Phase 1? Does the applicant demonstrate a continuing commitment to meaningful stakeholder (clinical, academic, policy, administrative, ehealth) and patient/citizen engagement in their Phase 2 plans?

Out of 5

10%

6. Finance
How appropriate is the proposal financially? Is the overall budget realistic and justified in terms of the aims and methods proposed? Are the costs appropriate and justified?

Out of 5

10%

7. Data Access
Does the application demonstrate that the necessary arrangement are in/will be in place to access the appropriate data required for the proposal?

Out of 5

15%

8. Commercialisation potential
Is there a clear business case for the project to lead to a marketable product, process or service and a clear plan to deliver that route to market?

Has the applicant demonstrated a well thought out business model for the solution post Phase 2 with regards to scaling up and adoption/deployment beyond the local Health Board level?

Out of 5

15%

 

Part C. Interview/pitch Assessment Criteria

Criteria

Score

Weighting

1. Understanding of scope/brief
Applicant demonstrates a clear understanding of the challenge brief and their proposal’s relevance to the competition objectives

Out of 5

20%

2. Understanding of healthcare data landscape
Applicant demonstrates an understanding of the challenges and opportunities in the healthcare data landscape and how it relates to their project

Out of 5

20%

3. Technical knowledge
Applicant has sufficient expertise and knowledge of the technical approaches and challenges relevant to their proposal

Out of 5

20%

4. Capabilities of team
The project has a team with the experience and skillsets (appropriate technical expertise and clinical input) required for their proposal

Out of 5

20%

5. Vision for Phase 2 and beyond
Applicant demonstrates a sound business model and route to market beyond Phase 2

Out of 5

20%

 

Successful applicants will be advised according to the published key dates and companies will be expected to mobilise rapidly to start the project and start as close to the Expected Start Date of 30 July 2018 as possible. 


CONDITIONS

The Cancer Innovation Challenge is a Scottish Funding Council funded PCP project led by The Data Lab Innovation Centre at the University of Edinburgh in partnership with Digital Health and Care Institute Scotland (DHI), Stratified Medicine Scotland (SMS), and NHS National Services Scotland. Partners include the Innovative Healthcare Delivery Programme (IHDP), Usher Institute, the NMAHP-RU at University of Stirling and the Health and Social Care Alliance Scotland. Contracts will be awarded by The University of Edinburgh acting in its capacity as The Data Lab (as the lead organisation).

By applying, applicants are consenting to the terms and conditions contained in the contract.  The terms of such contract shall ensure that IPRs generated will be retained by the applicant, although, in line with PCP principles, both the University of Edinburgh and NHS National Services Scotland may retain a non-exclusive royalty-free licence to use the IPRs or the right to acquire license rights to such IPRs at a fair market price.

R&D can cover activities such as solution exploration and design, prototyping, up to the original development of a limited by volume of first products or services in the form of a test series. "Original development of a first product or service may include limited production or supply in order to incorporate the results of field testing and to demonstrate that the product or service is suitable for production or supply in quantity to acceptable quality standards". R&D does not include commercial development activities such as quantity production, supply to establish commercial viability or to recover R&D costs, integration, customisation, incremental adaptations and improvements to existing products or processes

The sample contract is made available to applicants as part of the Competition Documents. 

 

END OF PHASE 2

The Cancer Innovation Challenge cannot guarantee procurement of the Contractor's proposed solution by NHS Scotland or any other party at the end of Phase 2. However, the Cancer Innvoation Challenge will endeavour to expose Phase 2 projects to as many potential routes to market (buyers, investors, enterprise agencies) as possible. 

 

CONTACT POINTS

Questions and comments are very welcome while the competition is open. Further information on the SBRI Framework can be found here. Questions about the SBRI programme not answered on the page should be addressed to support [at] innovateuk.gov.uk (subject: SBRI%20query)

Questions ON THE CHALLENGES AND SCOPE AND APPLICATION PROCESS of this competition should be addressed to info [at] cancerchallengescotland.com (subject: PROMs%20PREMs%20Phase%202%20ITT%20query)

Once the competition is closed, no further dialogue will be entered into. In order to streamline the process for this competition, feedback to unsuccessful applicants may not be available until after the contracts have been let.


DATA SHARING

Application Handling / Submission of Information/ Information Handling

The Competition is operated by the Cancer Innovation Challenge (@ The Data Lab in the University of Edinburgh) and its partners (DHI, SMS, NHS Services Scotland, IHDP, Usher Institute, NMAHP-RU, University of Edinburgh, University of Stirling, Health & Care Alliance Scotland) with the support of Innovate UK and your submitted application, together with any other information you provide at the application stage, will be deemed to be submitted to the Cancer Innovation Challenge on an individual basis for its storage, processing and use.  Also, any relevant information produced during the application process concerning your application may also be shared by the project partners, for its individual storage, processing and use. This means:

  • that any information given to or generated by The Cancer Innovation Challenge in respect of your application may be passed onto to the project partners listed above and vice versa; and
  • that the Cancer Innovation Challenge is directly responsible to you for its holding and processing of your information, including any personal data and confidential information, and will be held in accordance with its Information Management Policy and
  • that Submittable.com is directly responsible to you for its holding and processing of your information, including any personal data and confidential information, and will be held in accordance with its own policies
  • Innovate UK complies with the requirements of current Data Protection Law and is committed to upholding the data protection principles, and protecting your information. Further details with regards to personal data can be found here.  The Information Commissioner’s Office also has a useful guide, for organisations, which outlines the data protection principles. The link to this guide can be found here.

 

APPLY NOW

When is the interview/pitch?

Wednesday 4 July 2018. This date is NOT changeable. 

Where will the interview/pitch take place?

They will take place in the Board Room of the Data Lab office on 15 South College Street, Edinburgh, EH8 9AA.

What time will my interview/pitch be?

The interviews/pitches are scheduled as follows.

12.45 - 13.15 Jayex Technology 

13.20 - 13.50 Sharpe Analytics

13.55 - 14.25 Canon Medical Research Europe

Please arrive at least 15 minutes before your scheduled time.

What format will my interview/pitch take?

We would ask you to make a 10 minute presentation involving 5 slides (guidance below)

The presentation will then be followed by 5 minutes of demo of your solution (if applicable) and then 15-20 minutes (dependent on whether you had a demo) of Q&A by our Strategic Management Board

What should my presentation include?

You have 10 minutes to present 5 slides. They should include the following:

Slide 1. Introduction to your company and the team involved

Slide 2. Project overview and relevance to brief

Slide 3. Overview of Phase 1 learnings - feasibility

Slide 4. Technical overview 

Slide 5. Vision for your innovation beyond Phase 2

NB We will be strict on presentation timing

Should I send my presentation in advance?

YES. Please send your slides to Steph Wright on steph.wright [at] thedatalab.com by noon on Tuesday 3 July 2018.

Will the other companies be sitting in my interview/pitch?

No. Your interview/pitch will only be between your company and the Strategic Management Board, the Programme Executive and Project Manager. 

Recent Tweets

Cancer Challenge (1 hour ago)
RT @Patient_Data: On GDPR day, a reminder why it’s so important to use data responsibly to save lives https://t.co/wZZsKJpQJ9 Find out more…
Cancer Challenge (2 hours ago)
RT @DataLabScotland: Why Become a Data Scientist? (7+1 Selfish Reasons) - via Data36: https://t.co/7n5RIX2kPu #Data #DataScience

©2018 Cancer Innovation Challenge | Privacy and Cookie Policy | Terms of Use